BeOne Medicines Ltd ADR [ONC] stock is trading at $299.01, down -0.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ONC shares have gain 2.59% over the last week, with a monthly amount glided 22.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BeOne Medicines Ltd ADR [NASDAQ: ONC] stock has seen the most recent analyst activity on April 07, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $312. Previously, BofA Securities upgraded its rating to Buy on March 03, 2025, and elevated its price target to $320. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $288 on September 18, 2024. Macquarie started tracking with a Outperform rating for this stock on September 12, 2023, and assigned it a price target of $259. In a note dated August 17, 2023, Jefferies initiated an Buy rating and provided a target price of $287 on this stock.
BeOne Medicines Ltd ADR [ONC] stock has fluctuated between $155.75 and $308.87 over the past year. Currently, Wall Street analysts expect the stock to reach $303.5 within the next 12 months. BeOne Medicines Ltd ADR [NASDAQ: ONC] shares were valued at $299.01 at the most recent close of the market. An investor can expect a potential return of 1.5% based on the average ONC price forecast.
Analyzing the ONC fundamentals
BeOne Medicines Ltd ADR [NASDAQ:ONC] reported sales of 4.18B for the trailing twelve months, which represents a growth of 48.64%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.12 and Total Capital is -0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 291.62 points at the first support level, and at 284.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 302.84, and for the 2nd resistance point, it is at 306.68.
Ratios To Look Out For
For context, BeOne Medicines Ltd ADR’s Current Ratio is 1.96. As well, the Quick Ratio is 1.71, while the Cash Ratio is 1.27. Considering the valuation of this stock, the price to sales ratio is 7.85, the price to book ratio is 9.22.
Transactions by insiders
Recent insider trading involved AARON ROSENBERG, Officer, that happened on Aug 01 ’25 when 1190.0 shares were purchased. Global Head of R&D, Wang Lai completed a deal on Jul 29 ’25 to sell 4041.0 shares. Meanwhile, Global Head of R&D Wang Lai sold 259.0 shares on Jul 30 ’25.
